Combination of NEP 1-40 Treatment and Motor Training Enhances Behavioral Recovery After a Focal Cortical Infarct in Rats

Pei-chun Fang, PhD; Scott Barbay, PhD; Erik J. Plautz, PhD; Erica Hoover, BA; Stephen M. Strittmatter, MD, PhD; Randolph J. Nudo, PhD

Background and Purpose—Although myelin-associated neurite outgrowth disinhibitors have shown promise in restoring motor function after stroke, their interactive effects with motor training have rarely been investigated. The present study examined whether a combinatorial treatment (NEP 1-40 + motor rehabilitation) is more effective than either treatment alone in promoting motor recovery after focal ischemic injury.

Methods—Adult rats were assigned to one of 3 treatment groups (infarct/NEP 1-40 + motor training, infarct/NEP 1-40 only, infarct/motor training only) and 2 control groups (infarct/no treatment, intact/no treatment). A focal ischemic infarct was induced by microinjecting endothelin-1 into the motor cortex. Therapeutic treatments were initiated 1 week postinfarct and included intraventricular infusion of the pharmacological agent NEP 1-40 and motor training (skilled reach task). Behavioral assessments on skilled reach, foot fault, and cylinder tests were conducted before the infarct and for 5 weeks postinfarct.

Results—Rats demonstrated significant forelimb impairment on skilled reach and foot fault tests after the infarct. Although all infarct groups improved over time, motor training alone and NEP 1-40 alone facilitated recovery on the skilled reach task at the end of treatment Weeks 2 and 4, respectively. However, only NEP 1-40 paired with motor training facilitated recovery after 1 week of treatment in addition to treatment at Weeks 2 and 4. Finally, only the NEP 1-40 + motor training group maintained a performance level equivalent to that of the intact group over the entire period of posttreatment assessment.

Conclusions—This study suggests that behavioral training interacts with the effects of the axonal growth promoter, NEP 1-40, and may accelerate behavioral recovery after focal cortical ischemia. (Stroke. 2010;41:00-00.)

Key Words: cerebral infarct ■ motor cortex ■ rehabilitation ■ recovery ■ regeneration

It is widely recognized that functional recovery after stroke can be aided by rehabilitative training. Motor training induces neurophysiological and neuroanatomical plasticity in the motor cortex of intact brains as well as after stroke.1,2 Postinfarct training induces map reorganization, synaptogenesis, and dendritogenesis and promotes recovery.3 Functional reorganization of the cerebral cortex also occurs in human stroke survivors.4 Furthermore, clinical trials have demonstrated improvement in motor performance in chronic stroke survivors who underwent constraint-induced movement therapy.5 The underlying assumption is that motor recovery is related to adaptive cortical plasticity.

Pharmacological agents can serve as adjuvant therapies to enhance the effects of rehabilitative motor training. For example, administration of D-amphetamine combined with training results in improved recovery compared with D-amphetamine treatment alone.6 Other agents that improve recovery by completely different mechanisms might also benefit from an interactive effect with behavioral experience. One popular approach is to suppress myelin-associated inhibitors, NOGO-A, myelin-associated glycoprotein, and oligodendrocyte myelin glycoprotein, presumably increasing neurite outgrowth and axonal regeneration.7 Each of the 3 myelin-derived inhibitors act independently through the neuronal receptors NgR18 or PirB.9 Genetic deletion of NOGO-A or NgR1 expression in mice leads to enhanced recovery from stroke.10 Furthermore, administration of anti-NOGO-A antibodies can improve behavioral recovery after stroke11 or spinal cord injury.12 With the greater effectiveness achieved by blocking all 3 ligands, a soluble NgR decoy improves functional recovery from rodent stroke10 and spinal cord injury.13,14 A specific antagonist of NOGO-66 action at NgR1 is NEP 1-40 (NOGO extracellular peptide, residues 1 to 40), the administration of which increases locomotor recovery after rodent spinal cord injury.15,16

Received November 4, 2009; final revision received November 13, 2009; accepted November 16, 2009.
From the Landon Center on Aging (P.c.F., S.B., E.J.P., R.J.N.) and Molecular & Integrative Physiology (S.B., E.J.P., E.H., R.J.N.), University of Kansas Medical Center, Kansas City, Kan; and Yale University School of Medicine (S.M.S.), New Haven, Conn.
Correspondence to Randolph J. Nudo, PhD, KU Medical Center, Landon Center on Aging, 3901 Rainbow Boulevard, Kansas City, KS 66160. E-mail rnudo@kumc.edu
© 2010 American Heart Association, Inc.
Stroke is available at http://stroke.ahajournals.org DOI: 10.1161/STROKEAHA.109.572073
Although the use of NOGO antagonists is a potentially efficacious approach to recovery after stroke, the interactive effects of these agents with behavioral training have only been investigated in a single study in a spinal cord injury model. In that study, although anti-NOGO-A antibody and treadmill training applied individually improved locomotor performance, the combination treatment resulted in poorer motor performance. It is important to determine if this negative effect of combining neurite outgrowth disinhibitors with behavioral training extends to other central nervous system injury models.

Materials and Methods

Subjects and Group Assignment
A total of 37 adult male Long-Evans hooded rats (Harlan, Ind) were used. Preinfarct behavioral training and assessment were begun at 3 months of age and continued for 2 to 3 months. Each animal was singly housed in a standard animal room with a 12/12-hour light/dark cycle. Animals were allowed food and water ad libitum, although moderate food restriction was enforced before reach training and assessment. At 5 to 6 months of age, animals that met behavioral criteria were randomly assigned to one of 3 treatment groups or one of 2 control groups: NEP+TR: lesion + drug treatment + motor training (n = 8); NEP: lesion + drug treatment (n = 8); or TR: lesion + vehicle + motor training (n = 8). Control groups consisted of: LC: lesion + vehicle (n = 7); or NC: no lesion, vehicle (n = 6). Although there were 8 possible groups that could have been compared (including no lesion+treatment groups), the goal was to examine the effects of treatment on postinjury recovery. Thus, the important comparisons were made between the treatment groups and LC. NC was added to control for variation over time due to repeated testing. All procedures followed the National Institutes of Health guidelines for the care and use of laboratory animals and were approved by the University of Kansas Medical Center Animal Care and Use Committee.

Behavioral Training and Assessment
Forelimb motor performance was evaluated using 3 commonly used assessments of motor performance: skilled reach, foot fault, and cylinder tests. After infarct, rats were assessed 2 times per week during Week 1 and then once per week after postinfarct Weeks 2 and 5 (ie, after initiation of treatment; Figure 1).

Skilled Reach Test and Motor Training
Each animal was placed in a Plexiglas cylinder (26 cm long ¥ 25 cm high ¥ 15 cm wide) designed to restrict the use of either the right or left forelimb. The external shelf used to present food pellets was 5 cm from the bottom of the chamber and 2 distances were used to vary difficulty of the reach at 1 cm and 2 cm from the front of the chamber. A single food pellet (45 mg; BioServ) was delivered on each trial. Forelimb preference was determined during a preinfarct shaping period. Preinfarct training sessions (60 trials per session) were conducted until the rat obtained a success score of 70% with its preferred limb. Rats that did not attain this score were excluded from the study. Baseline performance was assessed over 2 to 3 weeks until the day of infarct. Postinfarct performance was assessed before treatment on Days 4 and 6 and then during treatment at the end of Weeks 2, 3, 4, and 5. Importantly, the skilled reach task was also used for rehabilitative training that began at postinfarct Week 2 (5 sessions/week, 60 trials/session) and continued for 28 days. Training began on the near well and was gradually titrated to the far well.

Foot Fault Test
Each rat was placed onto an elevated grid (57 cm ¥ 45 cm with 3.5 cm ¥ 3.5-cm grid opening) and allowed to explore for 2 minutes to assess forelimb use during locomotion. The number of times each forelimb was used and the number of slips made with each forelimb were recorded. Foot fault = (total number of slips made with impaired forelimb—intact forelimb)/total number of movements made with both forelimbs. A total of 7 foot fault assessments (one or 2 sessions/week) was conducted before the infarct.

Cylinder Test
Each rat was placed in a transparent cylinder (20 cm diameter, 30 cm height). Asymmetry scores were defined as the percentage of intact forelimb touches + ½ the percentage of bilateral forelimb touches for postural support over the first 60 touches. Sessions lasted 3 to 10 minutes.

Surgical Procedures and Drug Delivery
Within 1 week after preinfarct baseline assessments were completed, animals underwent a surgical procedure under aseptic conditions to create a focal cortical infarct and to implant an intraventricular cannula. Animals were anesthetized with ketamine (80 mg/kg, intraperitoneally) and xylazine (5 mg/kg, intramuscularly) to produce a surgical level of anesthesia. The scalp was shaved, the head stabilized in a stereotaxic frame, and the skin incised to expose the skull. Supplemental ketamine (20 mg/kg, intramuscularly) was administered as necessary.

Focal Infarct and Cannula Implant
Six 0.7-mm diameter holes were drilled into the skull over the dominant hemisphere (contralateral to the preferred forelimb): anteroposterior +1.5, +0.5, and −0.5 and mediolateral +2.5 and +3.5 from bregma, corresponding to the caudal forelimb area of the motor cortex. To induce the cortical infarct, 0.33 μL endothelin-1 (0.3 μg dissolved in 1 μL saline; Peninsula Laboratories, San Carlos, Calif) was injected into each hole (3 nL/s) at a depth of 1.5 mm from the cortical surface through a tapered micropipette (tip size 160 μm outer diameter, barrel size 900 μm outer diameter) attached to a Hamilton syringe. Bone wax was used to seal the injection holes. An additional hole was made over the nondominant hemisphere at anteroposterior −0.9 mm and mediolateral +2.0 mm from bregma. A cannula (0.36 mm outer diameter, Alzet brain infusion kit II; Alzet Scientific Products, Cupertino, Calif) connected to a catheter and filled with either vehicle (0.1 mol/L phosphate-buffered saline +dimethyl sulfoxide) or drug (NEP 1–40) was implanted into the lateral ventricle at a depth of 4.0 mm from the pial surface. 

Figure 1. Experimental timeline showing the drug treatment (pump implant) and/or motor training began on postinfarct Week 1 and continued for 4 weeks. Behavioral assessments were performed on postinfarct Days 4 and 6 (Week 1 data are the means of Days 4 and 6) and weekly during postinfarct Weeks 2 to 5.
by guest on April 11, 2017 http://stroke.ahajournals.org/ Downloaded from
28 days.
in 0.1 mol/L phosphate-buffered saline and then 20% glycerol plus
aldehyde fixative in 0.1 mol/L phosphate buffer. The brain was
transcardially with 0.9% sodium chloride and then 4% paraformal-

On postinfarct Day 47, animals were administered a lethal dose of
2 mL Beuthanasia (390 mg sodium pentobarbital) and perfused
Histology

/3% dimethyl sulfoxide; groups TR, LC, and
TR; NEP) or 2 mL of vehicle (97.5% phosphate-
buffered saline (groups NEP
/11001
/H11001

Other end of the catheter was sealed and secured under the skin.
Postoperatively, animals were given penicillin (0.15 mL, subcutane-
ously), saline (5 mL, subcutaneously), buprenorphine (0.05 mg/kg,
subcutaneously), and acetaminophen (20 mg/kg, orally).

Histology

Figure 2. A, Nissl stains showing the infarct (black arrowheads)
in the motor cortex in the right hemisphere from one representa-
tive rat. Left section is 1.8 mm rostral and right section is 0.6
caudal to bregma. Cannula track (white arrow) shown in the left
hemisphere. Scale bar=1 mm. B, There were no differences in
lesion volume between groups. NEP + TR, NEP 1-40 + motor
training; NEP, NEP 1-40; TR, motor training; LC, lesion only, no
treatment). Error bar=SEM.

Table 1. Percentage of Successful Food Pellet Retrievals Over 60 Trials (mean ± SEM)

<table>
<thead>
<tr>
<th>Group</th>
<th>Baseline</th>
<th>Postinfarct Week 1</th>
<th>Postinfarct Week 2 (Treatment Week 1)</th>
<th>Postinfarct Week 3 (Treatment Week 2)</th>
<th>Postinfarct Week 4 (Treatment Week 3)</th>
<th>Postinfarct Week 5 (Treatment Week 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>NC</td>
<td>74.16 ± 1.45</td>
<td>72.33 ± 0.33</td>
<td>72.33 ± 0.33</td>
<td>75.83 ± 3.68</td>
<td>77.17 ± 3.04</td>
<td>74.67 ± 4.43</td>
</tr>
<tr>
<td>NEP + TR</td>
<td>78.00 ± 1.69</td>
<td>56.71 ± 2.55</td>
<td>65.86 ± 3.56</td>
<td>80.43 ± 1.73</td>
<td>69.86 ± 5.59</td>
<td>75.29 ± 3.31</td>
</tr>
<tr>
<td>NEP</td>
<td>76.00 ± 2.15</td>
<td>57.13 ± 2.78</td>
<td>60.25 ± 3.66</td>
<td>59.13 ± 4.77</td>
<td>70.50 ± 4.70</td>
<td>70.88 ± 3.57</td>
</tr>
<tr>
<td>TR</td>
<td>73.88 ± 1.56</td>
<td>52.75 ± 4.83</td>
<td>61.75 ± 5.96</td>
<td>64.88 ± 4.30</td>
<td>62.13 ± 5.26</td>
<td>67.36 ± 5.48</td>
</tr>
<tr>
<td>LC</td>
<td>72.86 ± 2.11</td>
<td>49.29 ± 3.71</td>
<td>55.57 ± 2.82</td>
<td>55.29 ± 2.49</td>
<td>66.29 ± 3.76</td>
<td>61.86 ± 4.79</td>
</tr>
</tbody>
</table>

Statistical Analysis

Data were analyzed and compared among the groups (between-group
comparison; JMP software). Postmortem histology was analyzed with
a one-way analysis of variance to compare infarct volume
across groups. Behavioral data were also analyzed with analyses
of variance. Post hoc comparisons were analyzed with Student t least
square mean difference test to control for Type I error (α=0.05) and
simple effects analyses of variance (slice effects) to assess
group × time interactions. Percentage data were normalized with an
arcsine transformation.

Results

Histological Results

Nissl-stained sections revealed that the infarct destroyed all 6
layers of the caudal forelimb area. There was no obvious
evidence that the underlying white matter was damaged.
Also, the infarct was continuous throughout the territory of
the endothelin-1 injections, ranging from anteroposterior 1.8
to −0.9 mm from bregma (Figure 2A). The lesion was recon-
structed through StereoInvestigator software (MicroBrightField,
Colchester, Vt) and the volume measured by subtracting
injured from intact neocortex with the Cavalieri estimator.

Skilled Reach Test

Pretreatment Performance

Before the endothelin-1 infarct, there were no significant
differences among groups in successful reach and retrieval
skills (F[4,32]=1.24; P=0.31; Table 1). However, the infarct
significantly impaired skilled reach when assessed during
Week 1 (F[4,32]=6.36; P=0.0007). Post hoc analysis
showed that all infarct groups were significantly impaired
compared with NC. There were no significant differences
among the infarct groups.

Posttreatment Performance

There was a significant group effect (F[4,32]=17.88,
P=0.0001), time effect (F[3,96]=5.37, P=0.0001), and
group × time interaction (F[12,96]=2.31, P=0.012; Figure 3).
The interaction was analyzed with post hoc simple effects
analyses of variance, demonstrating a significant difference
among groups for each week of treatment (Table 2). Table 2

Figure 2. A, Nissl stains showing the infarct (black arrowheads) in the motor cortex in the right hemisphere from one representative rat. Left section is 1.8 mm rostral and right section is 0.6 caudal to bregma. Cannula track (white arrow) shown in the left hemisphere. Scale bar=1 mm. B, There were no differences in lesion volume between groups. NEP + TR, NEP 1-40 + motor training; NEP, NEP 1-40; TR, motor training; LC, lesion only, no treatment. Error bar=SEM.
also indicates each of the significant post hoc pairwise comparisons with LC and NC.

To summarize effects of the treatment groups compared with LC, TR demonstrated significant improvement only at the end of treatment Week 2, NEP at the end of treatment Week 4, and NEP+TR at the end of treatment Weeks 1, 2 and 4. Furthermore, compared with NC, TR was statistically indistinguishable at the end of treatment Week 4, NEP at the end of treatment Weeks 3 and 4, and NEP+TR at the end of each of the 4 treatment weeks.

Foot Fault Test

Pretreatment Performance

Before the endothelin-1 infarct, there were no significant differences in foot faults between groups (F[4,32]=1.78, P=0.16). During the first week after the lesion (pretreatment), there was a significant impairment in skilled locomotion on the foot fault task (F[4,32]=3.62, P=0.02). Post hoc analysis showed that there were no differences among infarct groups (NEP+TR, NEP, TR, and LC) and that all infarct groups were significantly impaired compared to NC (Figure 4).

Posttreatment Performance

There was no significant group effect (F[4,32]=2.29, P=0.065) nor interaction of group*time (F[12,96]=1.16, P=0.326; Figure 4) during any of the postinfarct weeks.

Cylinder Test

The cylinder test did not demonstrate a deficit in any of the groups (Figure 5; see “Discussion”)

Discussion

The purpose of this study was to determine the efficacy of NEP 1-40 plus motor training on motor recovery after a focal cortical infarct and whether the 2 treatments in combination interact. Our results showed that 2 of the 3 treatments, NEP 1-40 only (NEP) and NEP 1-40 combined with motor training (NEP+TR), facilitated recovery on a skilled reach task in that performance was superior to a lesion only control group (LC) at the end of the 4-week treatment regimen. However, the

Table 2. Post hoc Pairwise Comparisons

<table>
<thead>
<tr>
<th>Group</th>
<th>Week 2 (Treatment Week 1)</th>
<th>Week 3 (Treatment Week 2)</th>
<th>Week 4 (Treatment Week 3)</th>
<th>Week 5 (Treatment Week 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>F=4.03; P=0.005</td>
<td>F=13.60; P=7.9(10-3)</td>
<td>F=3.59; P=0.01</td>
<td>F=3.66; P=0.008</td>
</tr>
<tr>
<td>Versus lesion only group (LC)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NC</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>NEP+TR</td>
<td>*</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>NEP</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>TR</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>Versus intact control group (NC)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NEP+TR</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>NEP</td>
<td>*</td>
<td>NS</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>TR</td>
<td>*</td>
<td>*</td>
<td>NS</td>
<td>NS</td>
</tr>
<tr>
<td>LC</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
</tbody>
</table>

*F-values (4.96) from post hoc comparisons.
*Significant pairwise comparison (P<0.05).
Brackets indicate additional significant pairwise comparisons.
NS indicates nonsignificant.
combination treatment resulted in recovery earlier, because skilled reach performance was statistically superior to LC as early as treatment Week 1. Furthermore, although lack of statistical significance cannot be equated with negative proof, it is important to note that the combination treatment group’s performance on the skilled reach task was statistically indistinguishable from that of intact control animals throughout the treatment period. The effects of the combined treatment were most pronounced at treatment Week 2, when the combination treatment group performed significantly better than all other lesion groups (Table 2).

In a previous study in a spinal cord injury model, the myelin-associated neurite outgrowth disinhibitor anti-NOGO-A antibody was administered either alone or in combination with treadmill training. The combinatorial treatment resulted in poorer locomotion performance. Although there are several differences between this study and the present one, including the administration of NEP 1-40 rather than anti-NOGO-A antibody, it is possible that different injury models may be differentially responsive to combinatorial treatments of drug and behavioral training.

Alternatively, the effects of drug interaction with behavioral experience may be task-dependent. In the present study, we found significant drug–behavior interactions examining performance with the skilled reach task but not with the foot fault task. These results are very similar to those of a recent study using virtually an identical lesion model pairing d-amphetamine with skilled reach and grid walking. Like in our study, a positive interaction was found for skilled reach but not grid walking. It is possible that grid walking (foot fault task) is not sensitive enough to observe subtle deficits and hence interactive effects with drug treatment. Additionally, it is possible that reach training, presumably requiring more skill, may be a more effective modifier of synaptic plasticity than treadmill training. At least in intact rats, skilled reach training is more effective in modifying motor map organization and synaptic plasticity than unskilled motor activity. It should also be noted that in the present study, rats were not specifically trained on the foot fault task, although brief assessment was conducted weekly.

The lack of behavioral deficits using the cylinder test is surprising, because this test has been a reliable indicator of behavioral asymmetry in various infarct models. However, a recent study using endothelin-1 to produce a focal infarct in mice also found no deficit on this task, perhaps due to the lack of striatal involvement. However, in an earlier focal cortical infarct study in rats, these same investigators observed deficits on this task. Although lesion volume was not
reported, the figure suggests that lesions were larger than those in the present study. It would appear that the skilled reach test is a more sensitive measure of forelimb function than the cylinder test, especially after small cortical lesions.

The present study did not specifically address the mechanisms of recovery related to the various treatments. However, other lesion studies have shown that NEP 1-40 promotes axonal outgrowth, and rehabilitative training induces synaptogenesis and dendritic arborization. The outcome in the present study parallels findings on the interactive effects of d-amphetamine and task-dependent motor training in that the combination of these 2 treatments resulted in accelerated recovery compared with single treatment alone.

In summary, this study establishes a positive interactive effect of a treatment agent associated with axonal growth in combination with motor rehabilitation. NEP 1-40 plus motor training maximized motor recovery in that there were no differences between infarcted rats with the combinatorial treatment and normal rats, and combinatorial treatment accelerated the recovery process compared with either treatment alone. This treatment was effective when initiated 1 week after the infarct, suggesting the therapeutic application period for this combinatorial approach is relatively long.

Disclosures

None.

References

Combination of NEP 1-40 Treatment and Motor Training Enhances Behavioral Recovery After a Focal Cortical Infarct in Rats

Pei-chun Fang, Scott Barbay, Erik J. Plautz, Erica Hoover, Stephen M. Strittmatter and Randolph J. Nudo

*Stroke*. published online January 14, 2010;
*Stroke* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2010 American Heart Association, Inc. All rights reserved.
Print ISSN: 0039-2499. Online ISSN: 1524-4628

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://stroke.ahajournals.org/content/early/2010/01/14/STROKEAHA.109.572073.citation

**Permissions**: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Stroke* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

**Reprints**: Information about reprints can be found online at:
http://www.lww.com/reprints

**Subscriptions**: Information about subscribing to *Stroke* is online at:
http://stroke.ahajournals.org//subscriptions/